# data[].attributes.body
https://www.usp.org/our-impact/antimicrobial-resistance?gclid=Cj0KCQiA48j9BRC-ARIsAMQu3WR38Zzvl3WmeIFhQIKPg3SLEjc1nOhDHSDTVQ0VnGYUAduQ5zhdpsUaAvcNEALw_wcB

# data[].attributes.body
Antimicrobial resistance (AMR) causes an estimated 700,000 deaths annually worldwide, and every country is potentially affected. If not properly addressed, the number could grow to 10 million per year by 2050.

# data[].attributes.body
https://www.lanl.gov/museum/news/newsletter/2018/09/sot-sensor.php

# data[].attributes.body
Over-use of antibiotics leads to increasingly drug-resistant bacteria, contributing to their ability to evolve and adapt more quickly than scientists are able to create new antibiotics to combat them.

# data[].attributes.body
Use of antibiotics has exploded over the last 50 years. Over-use of antibiotics leads to increasingly drug-resistant bacteria, contributing to their ability to evolve and adapt more quickly than scientists are able to create new antibiotics to combat them. The short answer is a resounding maybe.

# data[].attributes.body
The antibiotic resistance crisis is the predictable outcome of how we have developed and used antibiotics since their discovery. If we continue to develop, use, and protect antibiotics for the next 80 years in the same way we have in the past 80, the future of the resistance problem is easy to predict.

# data[].attributes.body
New technologies and treatments—precision medicine, digital therapeutics, 3D printing, immunotherapy, gene and stem cell therapies and artificial intelligence—have arrived or are on their way.

# data[].attributes.body
Since 2000, more than 500 new medicines have been approved by the FDA, helping patients live longer, healthier lives. Medications are transforming many cancers into treatable conditions, reducing the impact of cardiovascular disease, offering new options for patients with hard-to-treat diseases like Alzheimer’s and Parkinson’s, and fighting even the rarest conditions.

# data[].attributes.body
- Hospital consolidation will continue and a number of big-power mega systems will emerge,
- Payment models designed to reward value will dominate in the future market landscape,
- Provider desire to share risk will increase the prevalence of value-based contracts,
- Payers will be an increasingly important stakeholder, due to their impact on patient routing,
- Physician will retain influence but will cede control to administrative stakeholders,
- Business model experimentation will continue as manufacturers change their strategies to succeed.

- Healthier workers

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378521/

# data[].attributes.headline
New medicines, antibiotic, bacteria resistance

# data[].attributes.subject
New medicines, antibiotic, bacteria resistance

# data[].attributes.body
Lack of new antibiotics threatens global efforts to contain drug-resistant infections

# data[].attributes.body
Antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases.

# data[].attributes.body
GARDP is a not-for-profit organization that develops new treatments to fight drug-resistant infections that pose the greatest threat to health, while working to ensure responsible use and sustainable access.

# data[].attributes.body
GARDP’s key priorities

Children’s antibiotics: GARDP is working to accelerate the development of new, improved and adapted antibiotics to treat drug-resistant infections in children, including sepsis in babies.

Serious bacterial infections: GARDP is accelerating the development of new treatments to address bacterial infections in hospitalized people for which there are limited or no treatment options.

Sexually transmitted infections: GARDP is accelerating the development of new treatments for difficult-to-treat and drug-resistant sexually transmitted infections, including gonorrhoea.

Discovery & exploratory: GARDP is screening chemical libraries to identify compounds that can be transformed into treatments for drug-resistant infections; identifying new chemical entities for preclinical and clinical development; and working with partners on a range of educational and knowledge sharing activities in antibiotic drug R&D